At X-Cutag, we are focused on  new drug development in oncology, infection, neurology, metabolism, and autoimmunology to address unmet medical needs by means of molecular structural modifications. Our team consists of scientists with extensive hands-on research and development experiences accumulated through collaborations with internationally renowned pharmaceutical companies, such as Pfizer, BMS, and Bayer.  Our unique structural modification platform“AcuMed Innovations”, has been able to build a drug product pipeline with 20 preclinical candidates (PCCs) within three years.  Assisted by Contract Research Organizations (CROs), we can quickly and effectively move forward PCCs into clinical trials with minimum investment.

Founder/Chairman: